

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 August 2025 (21.08.2025)



(10) International Publication Number
WO 2025/172693 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) *A61P 7/00* (2006.01)
A61K 31/444 (2006.01) *A61P 7/10* (2006.01)
A61K 45/06 (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/GB2025/050238

(22) International Filing Date:

07 February 2025 (07.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/553,054	13 February 2024 (13.02.2024)	US
63/645,661	10 May 2024 (10.05.2024)	US
63/705,839	10 October 2024 (10.10.2024)	US
63/733,582	13 December 2024 (13.12.2024)	US

Published:

— with international search report (Art. 21(3))

(71) Applicant: **KALVISTA PHARMACEUTICALS LIMITED** [GB/GB]; Porton Science Park, Bybrook Road, Porton Down, Salisbury Wiltshire SP4 0BF (GB).

(72) Inventors: **AUDHYA, Utpaul Kumar**; 40B Oak Rd, Canton, Massachusetts 02021 (US). **IVERSON, Matthew Scott**; 1499 Tallowood Circle, Cottonwood Heights, Utah 84093 (US). **SMITH, Michael David**; 2377 E Stringham Avenue, Salt Lake City, Utah 84109 (US). **YEA, Christopher Martyn**; c/o KalVista Pharmaceuticals Limited, Porton Science Park, Bybrook Road, Porton Down, Salisbury Wiltshire SP4 0BF (GB).

(74) Agent: **HOGGETT, Christopher James** et al.; Carpmaels & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: ORAL SEBETRALSTAT FOR THE TREATMENT OF AN ATTACK OF HEREDITARY ANGIOEDEMA

(57) Abstract: The present invention relates to treatments of hereditary angioedema (HAE). In particular, the present invention provides on-demand treatments of hereditary angioedema (HAE) by orally administering a plasma kallikrein inhibitor sebetralstat to a patient in need thereof on-demand.



WO 2025/172693 A1